VNRX

SEC source: 0001477932-21-007862 · form4.xml · derivative · entry 3

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires 2024-01-23

F2 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant).

F2 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant).

SEC source: 0001477932-21-007862 · form4.xml · derivative · entry 2

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2026-04-15

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant).

SEC source: 0001477932-21-007862 · form4.xml · derivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 65,000 shares

Expires 2022-04-15

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant).

SEC source: 0001477932-21-007863 · form4.xml · derivative · entry 6

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2028-01-23

F3 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant).

F3 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant).

SEC source: 0001477932-21-007863 · form4.xml · derivative · entry 5

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires 2024-01-23

F3 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant).

F3 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant).

SEC source: 0001477932-21-007863 · form4.xml · derivative · entry 4

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,467

Underlying: Common Stock · 33,467 shares

Expires 2027-03-30

F2 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on March 30, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on March 30, 2027 (ten years from the original date of grant).

F2 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on March 30, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on March 30, 2027 (ten years from the original date of grant).

SEC source: 0001477932-21-007863 · form4.xml · derivative · entry 3

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 33,467 shares

Expires 2023-03-23

F2 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on March 30, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on March 30, 2027 (ten years from the original date of grant).

F2 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on March 30, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on March 30, 2027 (ten years from the original date of grant).

SEC source: 0001477932-21-007863 · form4.xml · derivative · entry 2

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2026-04-15

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant).

SEC source: 0001477932-21-007863 · form4.xml · derivative · entry 1

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 65,000 shares

Expires 2022-04-15

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant).

SEC source: 0001477932-21-007790 · form4.xml · nonDerivative · entry 1

Plummer Nicholas · CIK 0001880653 · GC - Volition Diagnostics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,500

F1 · shares: In connection with his employment as General Counsel of Volition Diagnostics UK Limited, Mr. Plummer received restricted stock units subject to a 2-year vesting schedule, vesting as to 21,750 units on each of 11/01/22 and 11/01/23, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-21-006596 · form4.xml · derivative · entry 4

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2030-04-13

F2 · kind: The reported transactions involved a cancellation and reissuance of outstanding options upon agreement of the reporting person. The "old" options were originally granted on April 13, 2020 and vested in full at 12 months from the date of grant, and were exercisable until April 13, 2026. The "replacement" options are fully-vested on the date of grant and have an expiration date of April 13, 2030.

SEC source: 0001477932-21-006596 · form4.xml · derivative · entry 2

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2027-03-30

F1 · kind: The reported transactions involved a cancellation and reissuance of outstanding options upon agreement of the reporting person. The "old" options were originally granted on December 16, 2019, vested in full on the date of grant, and were exercisable until March 30, 2023. The "replacement" options are fully-vested on the date of grant and have an expiration date of March 30, 2027.

SEC source: 0001477932-21-006595 · form4.xml · derivative · entry 4

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2030-04-13

F2 · kind: The reported transactions involved a cancellation and reissuance of outstanding options upon agreement of the reporting person. The "old" options were originally granted on April 13, 2020 and vested in full at 12 months from the date of grant, and were exercisable until April 13, 2026. The "replacement" options are fully-vested on the date of grant and have an expiration date of April 13, 2030.

SEC source: 0001477932-21-006595 · form4.xml · derivative · entry 2

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,533

Underlying: Common Stock · 66,533 shares

Expires 2027-03-30

F1 · kind: The reported transactions involved a cancellation and reissuance of outstanding options upon agreement of the reporting person. The "old" options were originally granted on December 16, 2019, vested in full on the date of grant, and were exercisable until March 30, 2023. The "replacement" options are fully-vested on the date of grant and have an expiration date of March 30, 2027.

SEC source: 0001477932-21-006594 · form4.xml · derivative · entry 4

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2030-04-13

F2 · kind: The reported transactions involved a cancellation and reissuance of outstanding options upon agreement of the reporting person. The "old" options were originally granted on April 13, 2020 and vested in full at 12 months from the date of grant, and were exercisable until April 13, 2026. The "replacement" options are fully-vested on the date of grant and have an expiration date of April 13, 2030.

SEC source: 0001477932-21-006594 · form4.xml · derivative · entry 2

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,533

Underlying: Common Stock · 66,533 shares

Expires 2027-03-30

F1 · kind: The reported transactions involved a cancellation and reissuance of outstanding options upon agreement of the reporting person. The "old" options were originally granted on December 16, 2019, vested in full on the date of grant, and were exercisable until March 30, 2023. The "replacement" options are fully-vested on the date of grant and have an expiration date of March 30, 2027.

SEC source: 0001078782-21-000681 · primary_doc.xml · derivative · entry 2

Colman Alan · CIK 0001577873 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2025-07-23

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

SEC source: 0001078782-21-000681 · primary_doc.xml · derivative · entry 1

Colman Alan · CIK 0001577873 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2021-07-23

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

SEC source: 0001078782-21-000680 · primary_doc.xml · derivative · entry 2

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2025-07-23

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

SEC source: 0001078782-21-000680 · primary_doc.xml · derivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 35,000 shares

Expires 2021-07-23

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

SEC source: 0001078782-21-000679 · primary_doc.xml · derivative · entry 2

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2025-07-23

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

SEC source: 0001078782-21-000679 · primary_doc.xml · derivative · entry 1

Faulkes Martin Charles · CIK 0001577872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2021-07-23

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

SEC source: 0001078782-21-000678 · primary_doc.xml · derivative · entry 2

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2025-07-23

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old' options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old' options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

SEC source: 0001078782-21-000678 · primary_doc.xml · derivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 55,000 shares

Expires 2021-07-23

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old' options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old' options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

SEC source: 0001078782-21-000677 · primary_doc.xml · derivative · entry 2

Innes Guy Archibald · CIK 0001579377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2025-07-23

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

SEC source: 0001078782-21-000677 · primary_doc.xml · derivative · entry 1

Innes Guy Archibald · CIK 0001579377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2021-07-23

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

SEC source: 0001078782-21-000676 · primary_doc.xml · derivative · entry 2

Gaetan Michel · CIK 0001709503 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

Underlying: Common Stock · 2,000 shares

Expires 2025-07-23

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

SEC source: 0001078782-21-000676 · primary_doc.xml · derivative · entry 1

Gaetan Michel · CIK 0001709503 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,000 shares

Expires 2021-07-23

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

SEC source: 0001078782-21-000675 · primary_doc.xml · derivative · entry 2

Reynolds Cameron John · CIK 0001340610 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2025-07-23

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

SEC source: 0001078782-21-000675 · primary_doc.xml · derivative · entry 1

Reynolds Cameron John · CIK 0001340610 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 55,000 shares

Expires 2021-07-23

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

SEC source: 0001078782-21-000519 · primary_doc.xml · nonDerivative · entry 1

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,949

SEC source: 0001078782-21-000462 · primary_doc.xml · nonDerivative · entry 2

Innes Guy Archibald · CIK 0001579377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,534,975

SEC source: 0001078782-21-000463 · primary_doc.xml · nonDerivative · entry 1

Nguyen Kim · CIK 0001852492 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500

SEC source: 0001078782-21-000462 · primary_doc.xml · nonDerivative · entry 1

Innes Guy Archibald · CIK 0001579377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,484,975

SEC source: 0001078782-21-000416 · primary_doc.xml · nonDerivative · entry 2

Butera Salvatore Thomas · CIK 0001834339 · CEO-Volition Veterinary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

F2 · shares: In connection with his employment as Chief Executive Officer of Volition Veterinary Diagnostics Development, LLC, Dr. Butera received restricted stock units subject to a 3-year vesting schedule, vesting as to 50,000 units on each of 05/01/22, 05/01/23 and 05/01/24, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001078782-21-000283 · primary_doc.xml · nonDerivative · entry 1

Nguyen Kim · CIK 0001852492 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

F1 · shares: Ms. Nguyen received restricted stock units subject to a 2-year vesting schedule, vesting as to 7,500 units on each of 03/25/22 and 03/25/23, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001078782-21-000282 · primary_doc.xml · nonDerivative · entry 1

Brudnick Richard · CIK 0001692359 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

F1 · shares: Mr. Brudnick received restricted stock units subject to a 2-year vesting schedule, vesting as to 7,500 units on each of 03/25/22 and 03/25/23, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001078782-21-000416 · primary_doc.xml · nonDerivative · entry 1

Butera Salvatore Thomas · CIK 0001834339 · CEO-Volition Veterinary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: The reported transaction involved a cancellation of unvested restricted stock units upon Dr. Butera's resignation as a director of the issuer.

SEC source: 0001078782-21-000101 · primary_doc.xml · nonDerivative · entry 1

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,949

SEC source: 0001078782-21-000087 · primary_doc.xml · derivative · entry 1

Hughes Terig · CIK 0001841309 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,000

Underlying: Common Stock · 185,000 shares

Expires 2027-02-01

F1 · date: On February 1, 2021, the Reporting Person was granted a warrant to purchase up to 185,000 shares of Common Stock of the issuer at an exercise price of $4.90 per share. The warrant will vest in full twelve months from the date of grant (subject to continuous employment through such date).

F1 · shares: On February 1, 2021, the Reporting Person was granted a warrant to purchase up to 185,000 shares of Common Stock of the issuer at an exercise price of $4.90 per share. The warrant will vest in full twelve months from the date of grant (subject to continuous employment through such date).

SEC source: 0001078782-20-001006 · primary_doc.xml · derivative · entry 2

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2022-04-15

F1 · kind: The option to purchase an aggregate of 125,000 shares of Common Stock of VolitionRx Limited (the "Issuer"), was granted to Dr. Micallef on April 15, 2016 under the Issuer's 2015 Stock Incentive Plan and transferred to Borlaug Limited ("Borlaug"), a consulting firm, on April 20, 2016. Dr. Micallef is a controlling director of Borlaug and has voting and dispositive control over the Common Stock issuable to Borlaug upon the exercise of the option. The option was then transferred by Borlaug to Dr. Micallef on December 22, 2020.

SEC source: 0001078782-20-001006 · primary_doc.xml · derivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Borlaug Limited

Disclosed balance after: 0

Underlying: Common Stock · 125,000 shares

Expires 2022-04-15

F1 · kind: The option to purchase an aggregate of 125,000 shares of Common Stock of VolitionRx Limited (the "Issuer"), was granted to Dr. Micallef on April 15, 2016 under the Issuer's 2015 Stock Incentive Plan and transferred to Borlaug Limited ("Borlaug"), a consulting firm, on April 20, 2016. Dr. Micallef is a controlling director of Borlaug and has voting and dispositive control over the Common Stock issuable to Borlaug upon the exercise of the option. The option was then transferred by Borlaug to Dr. Micallef on December 22, 2020.

SEC source: 0001078782-20-001005 · primary_doc.xml · derivative · entry 4

Vanston David Cecil · CIK 0001703012 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Daughter

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2025-02-11

F2 · kind: The option to purchase an aggregate of 50,000 shares of Common Stock of the Issuer was granted to Mr. Vanston on February 11, 2019 under the Issuer's 2015 Plan. The option was transferred as a gift by Mr. Vanston to his daughter on December 22, 2020. Mr. Vanston disclaims beneficial ownership of the shares held by his daughter.

SEC source: 0001078782-20-001005 · primary_doc.xml · derivative · entry 3

Vanston David Cecil · CIK 0001703012 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires 2025-02-11

F2 · kind: The option to purchase an aggregate of 50,000 shares of Common Stock of the Issuer was granted to Mr. Vanston on February 11, 2019 under the Issuer's 2015 Plan. The option was transferred as a gift by Mr. Vanston to his daughter on December 22, 2020. Mr. Vanston disclaims beneficial ownership of the shares held by his daughter.

SEC source: 0001078782-20-001005 · primary_doc.xml · derivative · entry 2

Vanston David Cecil · CIK 0001703012 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Daughter

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2024-01-23

F1 · kind: The option to purchase an aggregate of 60,000 shares of Common Stock of VolitionRx Limited (the "Issuer"), was granted to Mr. Vanston on January 23, 2018, under the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"). The option was transferred as a gift by Mr. Vanston to his daughter on December 22, 2020. Mr. Vanston disclaims beneficial ownership of the shares held by his daughter.

SEC source: 0001078782-20-001005 · primary_doc.xml · derivative · entry 1

Vanston David Cecil · CIK 0001703012 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,000 shares

Expires 2024-01-23

F1 · kind: The option to purchase an aggregate of 60,000 shares of Common Stock of VolitionRx Limited (the "Issuer"), was granted to Mr. Vanston on January 23, 2018, under the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"). The option was transferred as a gift by Mr. Vanston to his daughter on December 22, 2020. Mr. Vanston disclaims beneficial ownership of the shares held by his daughter.

SEC source: 0001078782-20-000951 · primary_doc.xml · nonDerivative · entry 1

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,949

SEC source: 0001078782-20-000946 · primary_doc.xml · nonDerivative · entry 1

Butera Salvatore Thomas · CIK 0001834339 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

F1 · shares: Dr. Butera received restricted stock units subject to a 2-year vesting schedule, vesting as to 7,500 units on each of 12/01/21 and 12/01/22, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001078782-20-000894 · primary_doc.xml · nonDerivative · entry 3

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,949

SEC source: 0001078782-20-000894 · primary_doc.xml · nonDerivative · entry 2

TERRELL JASON BRADLEY MD · CIK 0001567531 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,149